Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure

Journal of Clinical Oncology

Volumn 19, Issue 17, 2001, Pages 3733-3739

  De Jongh, F E ^a   Verweij, J ^a   Loos, W J ^a   De Wit, R ^a   De Jonge, M J A ^a   Planting, A S T ^a   Nooter, K ^a   Stoter, G ^a   Sparreboom, A ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; IRINOTECAN; PROTEIN; TOPOTECAN;

ACCURACY; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; BODY SURFACE; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR;

EID: 0035449571     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.17.3733     Document Type: Article

References (28)

1. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
2. Body-surface area as a basis for dosing anticancer agents: Science, myth, or habit?
3. A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation
4. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
5. Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens
6. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
7. Plasma platinum levels: Relationship to cisplatin dose and nephrotoxicity
8. Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity
9. Cisplatin pharmacokinetics and pharmacodynamics in patients with squamous-cell carcinoma of the head/neck or esophagus
10. Cisplatin nephrotoxicity: Correlation with plasma platinum concentrations
11. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity
12. Relationship between the exposure to cisplatin: DNA-adduct formation in leucocytes and tumour response in patients with solid tumours
13. Individualization of cisplatin chemotherapy using AUC and DNA-adducts in WBC
14. Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin
15. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin
16. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence-dependent hematologic side effects
17. Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin
18. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
19. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors
20. Cisplatin binding sites on human albumin
21. Irreversible binding of cisplatin in rat serum
22. Pharmacokinetics of cis-diaminedichloroplatinum (II) after administration in hypertonic saline
23. Population pharmacokinetics and limited sampling model (LSM) of cisplatin
24. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: Analysis with the NONMEM program
25. Patient's age correlates with plasma and renal clearance of cisplatin (CDDP)
26. Gender-dependent pharmacokinetics of topotecan in adult patients
27. Gender-related differences in pharmacokinetics and their clinical significance
28. Clinical pharmacokinetics of oxaliplatin: A critical review